Respiporc Flu3

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
18-09-2020
产品特点 产品特点 (SPC)
18-09-2020
公众评估报告 公众评估报告 (PAR)
16-02-2021

有效成分:

inactivated influenza-A virus / swine

可用日期:

CEVA Santé Animale

ATC代码:

QI09AA03

INN(国际名称):

inactivated influenza-A virus, swine

治疗组:

Pigs

治疗领域:

Immunologicals

疗效迹象:

Active immunisation of pigs from the age of 56 days onwards, including pregnant sows, against swine influenza caused by subtypes H1N1, H3N2 and H1N2 to reduce clinical signs and viral lung load after infection.Onset of immunity: 7 days after primary vaccinationDuration of immunity: 4 months in pigs vaccinated between the age of 56 and 96 days and 6 months in pigs vaccinated for the first time at 96 days and above.Active immunisation of pregnant sows after finished primary immunisation by administration of a single dose 14 days prior to farrowing to develop high colostral immunity, which provides clinical protection of piglets for at least 33 days after birth.

產品總結:

Revision: 5

授权状态:

Authorised

授权日期:

2010-01-14

资料单张

                                18
B. PACKAGE LEAFLET
19
PACKAGE LEAFLET:
RESPIPORC FLU3
Suspension for injection for pigs
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder
Ceva Santé Animale
10 av. de La Ballastière
33500 Libourne
France
Manufacturer responsible for batch release:
IDT Biologika GmbH
Am Pharmapark
06861 Dessau-Rosslau
Germany
Ceva-Phylaxia Veterinary Biologicals Co. Ltd.
Szállás u. 5.
1107 Budapest
Hungary
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Respiporc FLU3 suspension for injection for pigs
3.
STATEMENT OF THE ACTIVE SUBSTANCES AND OTHER INGREDIENTS
Each dose of 2 ml contains:
ACTIVE SUBSTANCES:
Strains of inactivated Influenza A virus/swine/
Bakum/IDT1769/2003 (H3N2)
≥ 10.53 log
2
GMNU
1
Haselünne/IDT2617/2003 (H1N1)
≥ 10.22 log
2
GMNU
1
Bakum/1832/2000 (H1N2)
≥ 12.34 log
2
GMNU
1
1
GMNU = Geometric mean of neutralizing units induced in Guinea pigs
after twice immunisation with 0.5
ml of this vaccine
ADJUVANT:
Carbomer 971 P NF
2.0 mg
20
EXCIPIENT:
Thiomersal
0.21 mg
Clear, yellowish orange to pink coloured suspension for injection.
4.
INDICATION(S)
Active immunisation of pigs from the age of 56 days onwards including
pregnant sows against swine
influenza caused by subtypes H1N1, H3N2 and H1N2 to reduce clinical
signs and viral lung load after
infection.
Onset of immunity:
7 days after primary vaccination
Duration of immunity:
4 months in pigs vaccinated between the age of 56 and 96 days and
6 months in pigs vaccinated for the first time at 96 days and above.
Active immunisation of pregnant sows after finished primary
immunisation by administration of a single
dose 14 days prior to farrowing to develop high colostral immunity
which provides clinical protection of
piglets for at least 33 days after birth.
5.
CONTRAINDICATIONS
None.
6.
ADVERSE REACTIONS
A transient slight swelling may occur on very rare occasions after
vaccination at the site of injection,
regressing within 2 days. On
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Respiporc FLU3 suspension for injection for pigs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 2 ml contains:
ACTIVE SUBSTANCES:
Strains of inactivated Influenza A virus/swine/
Bakum/IDT1769/2003 (H3N2)
≥ 10.53 log
2
GMNU
1
Haselünne/IDT2617/2003 (H1N1)
≥ 10.22 log
2
GMNU
1
Bakum/1832/2000 (H1N2)
≥ 12.34 log
2
GMNU
1
1
GMNU = Geometric mean of neutralizing units induced in Guinea pigs
after twice immunisation with
0.5 ml of this vaccine
ADJUVANT:
Carbomer 971 P NF
2.0 mg
EXCIPIENT:
Thiomersal
0.21 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Clear, yellowish orange to pink coloured suspension for injection.
4.
CLINICAL PARTICULARS
4.1.
TARGET SPECIES
Pigs
4.2.
INDICATION FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of pigs from the age of 56 days onwards including
pregnant sows against swine
influenza caused by subtypes H1N1, H3N2 and H1N2 to reduce clinical
signs and viral lung load after
infection.
Onset of immunity:
7 days after primary vaccination
Duration of immunity:
4 months in pigs vaccinated between the age of 56 and 96 days and
6 months in pigs vaccinated for the first time at 96 days and above.
3
Active immunisation of pregnant sows after finished primary
immunisation by administration of a single
dose 14 days prior to farrowing to develop high colostral immunity
which provides clinical protection of
piglets for at least 33 days after birth.
4.3.
CONTRAINDICATIONS
None.
4.4.
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5.
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Not applicable.
Special precautions to be taken by the person administering the
veterinary medicinal product to animals
In case of accidental self-injection only a minor injection site
reaction is expected.
4.6.
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
A transient slight swelling may occur on very rare occasions after
vaccination at the site of injection,
reg
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 18-09-2020
产品特点 产品特点 保加利亚文 18-09-2020
公众评估报告 公众评估报告 保加利亚文 16-02-2021
资料单张 资料单张 西班牙文 18-09-2020
产品特点 产品特点 西班牙文 18-09-2020
公众评估报告 公众评估报告 西班牙文 16-02-2021
资料单张 资料单张 捷克文 18-09-2020
产品特点 产品特点 捷克文 18-09-2020
公众评估报告 公众评估报告 捷克文 16-02-2021
资料单张 资料单张 丹麦文 18-09-2020
产品特点 产品特点 丹麦文 18-09-2020
公众评估报告 公众评估报告 丹麦文 16-02-2021
资料单张 资料单张 德文 18-09-2020
产品特点 产品特点 德文 18-09-2020
公众评估报告 公众评估报告 德文 16-02-2021
资料单张 资料单张 爱沙尼亚文 18-09-2020
产品特点 产品特点 爱沙尼亚文 18-09-2020
公众评估报告 公众评估报告 爱沙尼亚文 16-02-2021
资料单张 资料单张 希腊文 18-09-2020
产品特点 产品特点 希腊文 18-09-2020
公众评估报告 公众评估报告 希腊文 16-02-2021
资料单张 资料单张 法文 18-09-2020
产品特点 产品特点 法文 18-09-2020
公众评估报告 公众评估报告 法文 16-02-2021
资料单张 资料单张 意大利文 18-09-2020
产品特点 产品特点 意大利文 18-09-2020
公众评估报告 公众评估报告 意大利文 16-02-2021
资料单张 资料单张 拉脱维亚文 18-09-2020
产品特点 产品特点 拉脱维亚文 18-09-2020
公众评估报告 公众评估报告 拉脱维亚文 16-02-2021
资料单张 资料单张 立陶宛文 18-09-2020
产品特点 产品特点 立陶宛文 18-09-2020
公众评估报告 公众评估报告 立陶宛文 16-02-2021
资料单张 资料单张 匈牙利文 18-09-2020
产品特点 产品特点 匈牙利文 18-09-2020
公众评估报告 公众评估报告 匈牙利文 16-02-2021
资料单张 资料单张 马耳他文 18-09-2020
产品特点 产品特点 马耳他文 18-09-2020
公众评估报告 公众评估报告 马耳他文 16-02-2021
资料单张 资料单张 荷兰文 18-09-2020
产品特点 产品特点 荷兰文 18-09-2020
公众评估报告 公众评估报告 荷兰文 16-02-2021
资料单张 资料单张 波兰文 18-09-2020
产品特点 产品特点 波兰文 18-09-2020
公众评估报告 公众评估报告 波兰文 16-02-2021
资料单张 资料单张 葡萄牙文 18-09-2020
产品特点 产品特点 葡萄牙文 18-09-2020
公众评估报告 公众评估报告 葡萄牙文 16-02-2021
资料单张 资料单张 罗马尼亚文 18-09-2020
产品特点 产品特点 罗马尼亚文 18-09-2020
公众评估报告 公众评估报告 罗马尼亚文 16-02-2021
资料单张 资料单张 斯洛伐克文 18-09-2020
产品特点 产品特点 斯洛伐克文 18-09-2020
公众评估报告 公众评估报告 斯洛伐克文 16-02-2021
资料单张 资料单张 斯洛文尼亚文 18-09-2020
产品特点 产品特点 斯洛文尼亚文 18-09-2020
公众评估报告 公众评估报告 斯洛文尼亚文 16-02-2021
资料单张 资料单张 芬兰文 18-09-2020
产品特点 产品特点 芬兰文 18-09-2020
公众评估报告 公众评估报告 芬兰文 16-02-2021
资料单张 资料单张 瑞典文 18-09-2020
产品特点 产品特点 瑞典文 18-09-2020
公众评估报告 公众评估报告 瑞典文 16-02-2021
资料单张 资料单张 挪威文 18-09-2020
产品特点 产品特点 挪威文 18-09-2020
资料单张 资料单张 冰岛文 18-09-2020
产品特点 产品特点 冰岛文 18-09-2020
资料单张 资料单张 克罗地亚文 18-09-2020
产品特点 产品特点 克罗地亚文 18-09-2020
公众评估报告 公众评估报告 克罗地亚文 16-02-2021